JSPR
Jasper Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.71
+3.23%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 21.0K | 1.1M | — | — | — |
| Gross Profit | (21.0K) | (1.1M) | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 36.7M | 60.5M | 55.8M | 51.8M | 34.6M |
| SG&A Expense | 18.4M | 18.9M | 20.4M | 17.1M | 16.6M |
| General & Admin Expense | 18.4M | 18.9M | 20.4M | 17.1M | 16.6M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 55.1M | 79.5M | 76.2M | 68.9M | 51.2M |
| Cost and Expenses | 55.2M | 80.5M | 76.2M | 68.9M | 51.2M |
| Operating Income (EBIT) | (55.2M) | (80.5M) | (76.2M) | (68.9M) | (51.2M) |
| Non-Operating | |||||
| Interest Income | 926.0K | 1.7M | 5.1M | 5.2M | 701.0K |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 926.0K | 1.7M | 5.1M | 5.2M | 701.0K |
| Other Non-Op Income/Expense | 23.4M | 4.7M | 5.0M | 4.4M | 13.5M |
| Non-Operating Income (excl Interest) | (23.4M) | (4.7M) | (5.0M) | (4.4M) | (13.5M) |
| EBT (Pre-Tax Income) | (31.8M) | (75.8M) | (71.3M) | (64.5M) | (37.7M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (31.8M) | (75.8M) | (71.3M) | (64.5M) | (37.7M) |
| Earnings from Cont. Ops | (31.8M) | (75.8M) | (71.3M) | (64.5M) | (37.7M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (31.8M) | (75.8M) | (71.3M) | (64.5M) | (37.7M) |
| Per Share | |||||
| Basic EPS | ($1.59) | ($3.95) | ($4.89) | ($6.18) | ($10.33) |
| Diluted EPS | ($1.59) | ($3.95) | ($4.89) | ($6.18) | ($10.33) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 28.7M | 19.2M | 14.6M | 10.4M | 3.6M |
| Diluted Shares Outstanding | 28.7M | 19.2M | 14.6M | 10.4M | 3.6M |
| Profitability Metrics | |||||
| EBITDA | (31.2M) | (74.7M) | (69.9M) | (63.4M) | (36.7M) |
| D&A | 540.0K | 1.1M | 1.4M | 1.1M | 975.0K |
| EBIT | (31.8M) | (75.8M) | (71.3M) | (64.5M) | (37.7M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026